Quest Diagnostics (NYSE:DGX) Updates FY 2025 Earnings Guidance

Key Points

• Quest Diagnostics has updated its FY 2025 earnings guidance to an EPS range of 9.760-9.840, surpassing the consensus estimate of 9.750.
• The company also provided a revenue guidance of $11.0 billion, exceeding the consensus estimate of $10.9 billion.
• Analysts maintain a consensus rating of "Moderate Buy" for Quest Diagnostics, with an average target price of $189.06.

Quest Diagnostics (NYSE:DGX - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 9.760-9.840 for the period, compared to the consensus earnings per share estimate of 9.750. The company issued revenue guidance of $11.0 billion-$11.0 billion, compared to the consensus revenue estimate of $10.9 billion.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on DGX shares. Truist Financial set a $195.00 price objective on shares of Quest Diagnostics in a research report on Tuesday, October 14th. Robert W. Baird reissued a "neutral" rating and issued a $194.00 target price on shares of Quest Diagnostics in a research note on Monday, August 25th. Barclays raised their price target on Quest Diagnostics from $185.00 to $190.00 and gave the company an "equal weight" rating in a research report on Thursday, October 2nd. Weiss Ratings reiterated a "buy (b)" rating on shares of Quest Diagnostics in a report on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on Quest Diagnostics from $160.00 to $178.00 and gave the company a "hold" rating in a research report on Wednesday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, Quest Diagnostics has a consensus rating of "Moderate Buy" and an average target price of $189.06.

Quest Diagnostics Stock Performance

NYSE DGX opened at $190.26 on Tuesday. The company has a 50-day simple moving average of $182.68 and a two-hundred day simple moving average of $176.41. Quest Diagnostics has a 12-month low of $146.91 and a 12-month high of $191.87. The firm has a market cap of $21.28 billion, a price-to-earnings ratio of 22.79, a PEG ratio of 2.51 and a beta of 0.56. The company has a quick ratio of 0.99, a current ratio of 1.09 and a debt-to-equity ratio of 0.71.

Quest Diagnostics (NYSE:DGX - Get Free Report) last released its earnings results on Tuesday, October 21st. The medical research company reported $2.60 earnings per share for the quarter, beating analysts' consensus estimates of $2.51 by $0.09. Quest Diagnostics had a return on equity of 15.24% and a net margin of 9.01%. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS. On average, equities analysts forecast that Quest Diagnostics will post 9.7 EPS for the current year.

Quest Diagnostics Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, October 20th. Stockholders of record on Friday, October 3rd were paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend was Friday, October 3rd. Quest Diagnostics's dividend payout ratio is 38.32%.

Insider Transactions at Quest Diagnostics

In related news, SVP Karthik Kuppusamy sold 8,269 shares of Quest Diagnostics stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $167.40, for a total value of $1,384,230.60. Following the transaction, the senior vice president directly owned 10,660 shares of the company's stock, valued at $1,784,484. The trade was a 43.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael E. Prevoznik sold 28,288 shares of the stock in a transaction on Tuesday, September 23rd. The shares were sold at an average price of $187.12, for a total transaction of $5,293,250.56. Following the sale, the senior vice president directly owned 38,117 shares of the company's stock, valued at $7,132,453.04. The trade was a 42.60% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 53,186 shares of company stock worth $9,647,471. Insiders own 8.16% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. MUFG Securities EMEA plc bought a new position in Quest Diagnostics during the 2nd quarter valued at approximately $59,000. Headlands Technologies LLC bought a new position in shares of Quest Diagnostics during the second quarter valued at approximately $171,000. Geneos Wealth Management Inc. lifted its stake in Quest Diagnostics by 20.6% in the second quarter. Geneos Wealth Management Inc. now owns 1,134 shares of the medical research company's stock worth $204,000 after acquiring an additional 194 shares during the period. Brevan Howard Capital Management LP bought a new stake in Quest Diagnostics in the second quarter valued at $208,000. Finally, IHT Wealth Management LLC purchased a new position in Quest Diagnostics during the 2nd quarter valued at $223,000. Hedge funds and other institutional investors own 88.06% of the company's stock.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.